NEWSRSV Vaccines for the World - Registration openWe are pleased to announce that the on-line registration is now openend for the "RSV Vaccines For The World" conference to be held in Málaga, Spain on November 29th - December 1st, 2017.
Be PART OF THE 4th RSV Expert MeetingWe are delighted to announce 4th Annual ReSViNET Meeting "RSV Vaccines For The World". This yearly RSV expert meeting is devoted exclusively to RSV infection prevention and treatment and will take place in Málaga, Spain.
Please click here for more information about the meeting 
|
A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants
Qing Zhu,1*† Jason S. McLellan,2† Nicole L. Kallewaard,1 Nancy D. Ulbrandt,1 Susan Palaszynski,1 Jing Zhang,1 Brian Moldt,1 Anis Khan,3 Catherine Svabek,1 Josephine M. McAuliffe,1 Daniel Wrapp,2 Nita K. Patel,1 Kimberly E. Cook,4 Bettina W. M. Richter,1 Patricia C. Ryan,5 Andy Q. Yuan,4 JoAnn A. Suzich1* ReSViNET sites
|
about REsvinet
RSV (Respiratory Syncytial Virus) infection is the second most important cause of death during infancy, especially in developing countries. RSV infection has also been linked to an increased risk in the development of chronic airway disease in later life. Therefore, research on RSV is crucial.
In order to improve research on RSV, ReSViNET (Respiratory Syncytial Virus Network) has been established. In this network, expertise and leadership are combined in order to decrease the global burden of RSV. It is our goal to improve knowledge of RSV epidemiology and to develop safe and effective therapeutic and preventive interventions.
In order to improve research on RSV, ReSViNET (Respiratory Syncytial Virus Network) has been established. In this network, expertise and leadership are combined in order to decrease the global burden of RSV. It is our goal to improve knowledge of RSV epidemiology and to develop safe and effective therapeutic and preventive interventions.
